The University of British Columbia
UBC - A Place of Mind
The University of British Columbia
Faculty of Medicine
  • Home
  • Admissions
  • About
    • Strategic Plan
    • Indigenous Health
    • Leadership
    • Academic & Research Units
    • Campuses
    • Facts & Figures
    • Careers
    • Contact
  • News
    • Events
    • Pathways Magazine
  • Education
    • Programs
    • Faculty Development
    • Health Education Scholarship
    • Continuing Professional Development
  • Research
    • Priority Areas
    • COVID-19 Clinical Research Coordination Initiative
    • Research in Focus
    • Centres & Institutes
    • National Prizes
  • Giving
    • Impact of Giving
    • By the Numbers
    • Ways to Give
    • Webinar Series
    • Contact Us
  • Prospective Students
  • Current Learners
    • Policies & Procedures
    • Professionalism & Respectful Environments
    • Mistreatment Help
    • MD & Undergrad Research
    • Summer Student Research Program
    • Grad & Postdoc Resources
  • Faculty & Staff
  • Clinical Faculty
    • Becoming Clinical Faculty
    • Appointment Policy & Compensation Terms
    • Teaching Tracking & Payment System
    • Services & Perks
    • Career Development
    • Awards
    • Advisory Council
    • Contacts
  • Alumni
» Home » News » Enzyme may be key to stopping fatal sepsis outcomes

Contact

Communications
UBC Faculty of Medicine
Email: communications.med@ubc.ca
Office: 604.822.2421

Share this Story

Enzyme may be key to stopping fatal sepsis outcomes

By Digital Comms | October 15, 2014

Keith Walley

Keith Walley

Controlling levels of the human enzyme PCSK9 could be the difference between life and death for patients with severe sepsis — an inflammatory reaction to infection that threatens to shut down vital organs.

Keith Walley, a Professor in the Department of Medicine, found that inhibiting or reducing PCSK9 could allow the patient’s body to clear toxic remnants of bacteria and fungi destroyed by antibiotics.  Getting rid of the infection’s waste may improve the patient’s outcomes and survival rates.

Treatment of mice with severe sepsis using a PCSK9 inhibitor increased survival.  Mice with a genetic variation that reduced the levels of PCSK9 also showed improved sepsis outcomes and survival rates.

Many pharmaceutical companies are currently developing PCSK9 inhibitors to increase clearance of cholesterol thereby lowering cardiovascular risk.  This raises the possibility that a PCSK9 inhibitor could increase survival for patients with sepsis — a condition accounts for four of the top ten causes of death worldwide.

The research, published Oct. 15 in Science Translation Medicine, was conducted by Dr. Walley’s UBC team, the Centre for Heart Lung Innovation at St. Paul’s Hospital and collaborators at the University of Pennsylvania and Chiba University in Japan.

Contact Information

Communications
UBC Faculty of Medicine
Email: communications.med@ubc.ca
Office: 604.822.2421

Share this Story

Faculty of Medicine
317 - 2194 Health Sciences Mall
Vancouver, BC Canada V6T 1Z3
Tel 604 822 2421
Website med.ubc.ca
Find us on
     
Back to top
The University of British Columbia
  • Emergency Procedures |
  • Terms of Use |
  • Copyright |
  • Accessibility